Navigation Links
Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M.
Date:3/13/2009

on.com for more information.

What is this Lawsuit About?

Lead Plaintiff, on behalf of the Class, alleges that the Defendants knowingly or recklessly made false and misleading statements and omissions that failed adequately to disclose serious and widespread deficiencies in Schering-Plough's manufacturing and quality operations and that such deficiencies gave rise to a serious risk that the United States Food and Drug Administration would delay approval of the company's New Drug Application for an allergy drug known as Clarinex(R). Lead Plaintiff alleges that as a result of these false and misleading statements and omissions, Defendants violated Section 10(b), 20(a) and 20A of the Securities Exchange Act of 1934.

Defendants deny any wrongdoing and specifically have denied the claims made by Lead Plaintiff in this Action. Defendants maintain that Schering-Plough's manufacturing and quality issues were known by the investing public and were duly and accurately disclosed in Schering-Plough's filings with the Securities and Exchange Commission. Defendants further maintain that Schering-Plough's public statements during the Class Period did not predict or promise that Clarinex(R) would be approved, and that, in any event, Defendants had no basis to believe that the approval of Clarinex(R) would be delayed.

The Court did not decide which side was right. Both sides have agreed to the Settlement to resolve this case. The two sides disagree on whether Class Members could have received money had the lawsuit gone to trial.

What Does the Settlement Provide?

Schering-Plough has agreed to pay one hundred and sixty-five million dollars ($165,000,000) in cash in settlement of this case. These funds will be distributed to eligible Class Members who send in valid claim forms, after the payment of court-approved legal fees and expenses, and the costs o
'/>"/>

SOURCE Barrack, Rodos & Bacine
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. In the Midst of a National Nurse Shortage Crisis ... Nurses Celebrate Landmark Legal Settlement That Will Help Ensure Fair Compensation & Bring More RNs to the Bedside
2. Important Deadlines Near for $21 Million Class Action Settlement That Provides Consumers With Money Back for Over 200 Prescription Drugs
3. Endo and Penwest Announce Settlement of Opana(R) ER Litigation
4. CVS Caremark Issues Statement on Settlement Concerning Disposal of Patient Information at its Retail Stores
5. Federal Trade Commission Files Complaint Against Par Pharmaceutical Over Court-Approved AndroGel(R) Litigation Settlement
6. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
7. Lawyers React to Texas Attorney Generals Lawsuit, Settlement Against Houstons Memorial Hermann
8. Justice Department Reaches Settlement Over Conditions at South Carolina Nursing Care Center
9. Justice Department Reaches Settlement With Georgia Regarding States Seven Psychiatric Hospitals
10. Rochester Medical Announces Settlement With TYCO Healthcare Group, L.P., Now Operating as Covidien Ltd.
11. AMA Claims Victory With Record Breaking Settlement in Case Against Insurer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 CHI-California Healthcare ... and the California congressional delegation, joined by over ... industry user fees paid to the U.S. Food ... that future across-the-board cuts will not include user ... FY14 Agriculture, Rural Development and FDA Appropriations Bill. ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- Drugs commonly used ... side effects that can interfere with vision, according to ... analogues (PGAs), which are used to reduce eye pressure, ... and changes in eye color, the researchers said, suggesting ... for PGAs. Doctors should be conservative when ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Let’s face it: ... is not uncommon for the majority of people to be ... is due to a coffee addiction or simply genetics, yellowish ... procedures are so popular. , Herald Square Dental ... very effective whitening system: Venus White Max. , Teeth ...
(Date:5/24/2013)... 24, 2013 Area homeowners dreaming about owning ... hot tubs to choose from at factory-direct pricing during the ... sales event takes place at Emerald Pool and Patio ... , Jacuzzi, the industry's leading hot tub brand, scheduled the ... country. The event will feature popular hot tub models at ...
(Date:5/24/2013)... York, New York (PRWEB) May 24, 2013 ... Vinci lawsuit involving Intuitive Surgical Inc.’s da Vinci ... According to court records, a Washington State Court jury ... committed negligence in training a surgeon who performed a ... years later. The patient’s family had alleged in ...
Breaking Medicine News(10 mins):Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3
... Senetek PLC (OTC,Bulletin Board: SNKTY), a Life ... target the science of healthy aging, today announced,the ... ., Mr. Frank Massino, Senetek,s Chairman and ... greater visibility to Senetek at this,significant time in ...
... good models for human biology and disease. Now, ... that is transparent throughout its life. The new ... and observe processes like tumor metastasis and blood production ... fish, described in the February 7 issue of Cell ...
... Prescription pediatric drugs represent,an enormous market, with manufacturer sales ... forecast at a modest 3.2%, reaching $43,billion by 2011, ... 11.7%, is,expected to achieve the highest growth rate of ... new report The World Market for,Pediatric Drugs., The ...
... N.C., Feb. 6 With pharmaceutical sales,forces shrinking ... force will be a key driver in organizational ... structure conducive to motivating sales people,properly communicating goals ... both,organizational and personal goals., The Best Practice ...
... 6 Nile Therapeutics,Inc. (OTC Bulletin Board: NILT), ... been dosed in its Phase Ib, multi-center, open-label,ascending ... candidate,CD-NP, a novel chimeric natriuretic peptide, in development ... "We are very excited that dosing has begun ...
... to seek restatement of Beth Israel Deaconess,Medical Center audit, ... Douglas T. Linde should apply the same Sarbanes-Oxley,standards used ... role on the board of Beth Israel Deaconess Medical ... Workers East. Linde is,also the president and CFO of ...
Cached Medicine News:Health News:Senetek PLC Announces Launch of New Website 2Health News:Transparent fish to make human biology clearer 2Health News:Transparent fish to make human biology clearer 3Health News:Diabetes, Growth Disorders Drive Sales of Pediatric Hormone Drugs 2Health News:Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies 2Health News:Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP 2Health News:Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP 3Health News:Boston Properties Executive and Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2
(Date:5/23/2013)... de mayo de 2013  Volcano Corporation (NASDAQ: ... fabricante de herramientas de precisión para terapia guiadas ... la enfermedad vascular periférica y coronaria, anunció hoy ... enosine V asodilator I ndependent ... sesión de ensayo clínico hot line late breaking ...
(Date:5/23/2013)... OAKS, Calif. , May 23, 2013 Amgen ... Bank 38 th Annual  Healthcare Conference on Thursday, May ... Boston , beginning at 9:20 a.m. Eastern Daylight Time. ... Relations at Amgen, will present at the conference. Live audio ... on Amgen,s website, www.amgen.com , under Investors. A replay ...
(Date:5/23/2013)... RIVER EDGE, N.J. , May 23, 2013 /PRNewswire/ ... ), a commercial stage medical device company that develops ... the successful completion of its rights offering.  In addition, ... company,s March 2011 warrants expired on May 17, 2013. ... proceeds of $3.0 million from the rights offering.   A ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... WILMINGTON, Del. , April 30 ... and Drug Administration (FDA) has approved VIMOVO™ ... of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ... gastric ulcers in patients at risk of developing NSAID-associated ...
... The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine ... as its July 2010 "Stock to Study" and Gilead ... for investors, informational and educational use. , ... "The committee chose Teva Pharmaceutical Industries because of the tremendous ...
Cached Medicine Technology:FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 2FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 3FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 4FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 5FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 6FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 7FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 8FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 9BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 2BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: